Patient-Specific Minimal Residual Disease Primers Amplify with Uniformly High Efficiency

Area of Science:

• Molecular Biology
• Biotechnology
• Medical Diagnostics

Background:

• Polymerase Chain Reaction (PCR) is crucial for quantifying minimal residual disease (MRD).
• Variations in PCR primer amplification efficiency (AE) have limited the accuracy of MRD quantification.
• Accurate AE measurement is essential for reliable clinical applications of PCR.

Purpose of the Study:

• To develop a precise and simple method for determining PCR primer amplification efficiency (AE).
• To validate the new method for quantifying minimal residual disease (MRD) primers.
• To establish a standardized approach for AE determination transferable to other laboratories.

Main Methods:

• A novel
• one copy Ct
• method was developed using single copies of target molecules and microplate-based PCR.
• Mean one copy Ct values were calibrated against AE determined by standard regression analysis.
• AE of test primers was calculated by relating their one copy Ct to calibrated values.

Main Results:

• The
• one copy Ct
• method demonstrated significantly higher precision than traditional regression analysis.
• Amplification efficiencies for MRD primers and primers for eight other genes were consistently high, often exceeding 95% and approaching 100%.
• A transferable primer/plasmid standard was created to facilitate inter-laboratory use.

Conclusions:

• The
• one copy Ct
• method provides a simple, accurate, and precise way to determine PCR primer AE.
• This method enhances the reliability of PCR-based quantification, particularly for minimal residual disease monitoring.
• Standardization of AE measurement will improve the consistency and comparability of PCR results across different research settings.